References
- Di Ieva A, Rotondo F, Syro LV, et al. Aggressive pituitary adenomas-diagnosis and emerging treatments. Nat Rev Endocrinol. [Internet] 2014;10:423–435. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24821329
- Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med. [Internet] 1994;120:817–820. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8154641
- Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. [Internet] 2016;1–18. Available from: http://link.springer.com/10.1007/s00401-016-1545-1
- Cheng JS, Salinas R, Molinaro A, et al. A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass. J Clin Neurosci. 2015;22:155–160.
- Elenkova A, Genov N, Abadzhieva Z, et al. Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance. Exp Clin Endocrinol Diabetes. 2013;121:201–205.
- Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65:265–273.
- Wong A, Eloy JA, Couldwell WT, et al. Update on prolactinomas. Part 1: clinical manifestations and diagnostic challenges. J Clin Neurosci. 2015;22:1562–1567.
- Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. J Neurosurg. [Internet] 2011;114:1369–1379. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21214334
- Oh MC, Kunwar S, Blevins L, et al. Medical Versus Surgical Management of Prolactinomas. Neurosurg Clin N Am. 2012;23:669–678.
- Kreutzer J, Buslei R, Wallaschofski H, et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008;158:11–18.
- Couldwell WT, Weiss MH, Laws ER. Prolactinomas. N Engl J Med. [Internet] 2004;350:1054–1057. author reply 1054–1057. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15002121
- Liu JK, Couldwell WT. Pituitary apoplexy in the magnetic resonance imaging era: clinical significance of sphenoid sinus mucosal thickening. J Neurosurg. 2006;104:892–898.
- Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60:698–705.
- Wong A, Eloy JA, Couldwell WT, et al. Update on prolactinomas. Part 2: treatment and management strategies. J Clin Neurosci. 2015;22:1568–1574.
- Colao A, di Sarno A, Pivonello R, et al. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs. [Internet] 2002;11:787–800. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12036422
- Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005;8:43–52.
- Tyrrell JB, Lamborn KR, Hannegan LT, et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery. 1999;44:254–263.
- Losa M, Mortini P, Barzaghi R, et al. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab. 2002;87:3180–3186.
- Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary. 2002;5:55–65.
- Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. [Internet] 2011;96:273–288.
- Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. [Internet] 1994;331:904–909. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199410063311403
- Pascal-Vigneron V, Weryha G, Bosc M, et al. Hyperprolactinemic amenorrhea: treatmentwith cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med. [Internet] 1995;753–757. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/094/CN-00115094/frame.html
- Cook DM. Long-term management of prolactinomas–use of long-acting dopamine agonists. Rev Endocr Metab Disord. [Internet] 2005;6:15–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15711910
- Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and Prolactinomas. Endocrinol Metab Clin North Am. 2008;37:67–99.
- Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93:4721–4727.
- Boguszewski CL, Dos Santos CMC, Sakamoto KS, et al. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012;15:44–49.
- Auriemma RS, Pivonello R, Ferreri L, et al. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am. 2015;44:89–97.
- Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179–1183.
- Delgado V, Biermasz NR, Van Thiel SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf). 2012;77:99–105.
- Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013;169:359–366.
- Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:43–51.
- Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349:2023–2033.
- Halperin Rabinovich I, Cámara Gómez R, García Mouriz M, et al. Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia. Endocrinol Nutr. [Internet] 2013;60:308–319. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23477758
- Ji MJ, Kim JH, Lee JH, et al. Best candidates for dopamine agonist withdrawal in patients with prolactinomas. Pituitary. [Internet] 2017;20:578–584. Available from: http://link.springer.com/10.1007/s11102-017-0820-z
- Barber TM, Kenkre J, Garnett C, et al. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol (Oxf). 2011;75:819–824.
- Anagnostis P, Adamidou F, Polyzos SA, et al. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: A single center experience. Pituitary. 2012;15:25–29.
- Barker FG, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the united states, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab. 2003;88:4709–4719.
- Salvatori R. Surgical treatment of microprolactinomas: pros. Endocrine. 2014;47:725–729.
- Bloomgarden E, Molitch ME. Surgical treatment of prolactinomas: cons. Endocrine. 2014;47:730–733.
- Amar AP, Couldwell WT, Chen JCT, et al. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg. [Internet] 2002;97:307–314. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12186458
- Hofstetter CP, Shin BJ, Mubita L, et al. Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas. Neurosurg Focus. [Internet] 2011;30:E10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21456921
- Liu JK, Couldwell WT. Contemporary management of prolactinomas. Neurosurg Focus. [Internet] 2004;16:E2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15191331
- Turner HE, Adams CBT, Wass JAH. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists? Eur. J Endocrinol. 1999;140:43–47.
- Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol. 2001;54:139–150.
- McLaughlin N, Laws ER, Oyesiku NM, et al. Pituitary centers of excellence. Neurosurgery. 2012;71:916–926.
- Vroonen L, Jaffrain-Rea ML, Petrossians P, et al. Prolactinomas resistant to standard doses of cabergoline: A multicenter study of 92 patients. Eur J Endocrinol. 2012;167:651–662.
- Hamilton DK, Vance ML, Boulos PT, et al. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary. 2005;8:53–60.
- Faria MA Jr., Tindall GT. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. J Neurosurg. [Internet] 1982;56:33–43. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7198681
- Hardy J, Beauregard H, Robert F. Prolactin-secreting pituitary adenomas: transsphenoidal microsurgical treatment. Clin Neurosurg. [Internet] 1980;27:38–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7196815
- Thomson JA, Davies DL, McLaren EH, et al. Ten year follow up of microprolactinoma treated by transsphenoidal surgery. BMJ. [Internet] 1994;309:1409–1410. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2541328&tool=pmcentrez&rendertype=abstract
- Andereggen L, Frey J, Andres RH, et al. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine. 2017;55:223–230.
- Andereggen L, Frey J, Andres RH, et al. Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health. World Neurosurg. 2017;97:595–602.
- Fleseriu M, Yedinak C, Campbell C, et al. Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions. J Neurosurg. 2009;110:354–358.
- Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: A structured review and meta-analysis. Pituitary. 2012;15:71–83.
- Feigenbaum SL, Downey DE, Wilson CB, et al. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab. 1996;81:1711–1719.
- Nelson PB, Goodman M, Maroon JC, et al. Factors in predicting outcome from operation in patients with prolactin-secreting pituitary adenomas. Neurosurgery. 1983;13:634–641.
- Raverot G, Wierinckx A, Dantony E, et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab. 2010;95:1708–1716.
- Serri O, Rasio E, Beauregard H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. [Internet] 1983;309:280–283. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6866052
- Massoud F, Serri O, Hardy J, et al. Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surg Neurol. 1996;45:341–346.
- Parl FF, Cruz VE, Cobb CA, et al. Late recurrence of surgically removed prolactinomas. Cancer. 1986;57:2422–2426.
- Arafah BM, Harrington JF, Madhoun ZT, et al. Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy. J Clin Endocrinol Metab. 1990;71:323–328.
- Charpentier G, de Plunkett T, Jedynak P, et al. Surgical treatment of prolactinomas. Short- and long-term results, prognostic factors. Horm Res. [Internet] 1985;22:222–227. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4054842
- Schlechte JA, Sherman BM, Chapler FK, et al. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J Clin Endocrinol Metab. 1986;62:1296–1301.
- Rodman EF, Molitch ME, Post KD, et al. Long-term follow-up of transsphenoidal selective adenomectomy for prolactinoma. JAMA. [Internet] 1984;252:921–924. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6431121
- Dorward NL. Endocrine outcomes in endoscopic pituitary surgery: a literature review. Acta Neurochir (Wien). 2010;152:1275–1279.
- Rotenberg B, Tam S, Ryu WHA, et al. Microscopic versus endoscopic pituitary surgery: A systematic review. Laryngoscope. 2010;120:1292–1297.
- Strychowsky J, Nayan S, Reddy K, et al. Purely endoscopic transsphenoidal surgery versus traditional microsurgery for resection of pituitary adenomas: systematic review. J Otolaryngol Head Neck Surg. 2011;40:175–185.
- Dallapiazza RF, Jane JA. Outcomes of endoscopic transsphenoidal pituitary surgery. Endocrinol Metab Clin North Am. 2015;44:105–115.
- Jho HD, Carrau RL. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg. 1997;87:44–51.
- Dehdashti AR, Ganna A, Karabatsou K, et al. Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series. Neurosurgery. 2008;62:1006–1015.
- Frank G, Pasquini E, Farneti G, et al. The endoscopic versus the traditional approach in pituitary surgery. Neuroendocrinology. 2006;83:240–248.
- Cappabianca P, Cavallo LM, Colao A, et al. Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. J Neurosurg. [Internet] 2002;97:293–298. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12186456
- Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172:R205–R213.
- Auriemma RS, Perone Y, Di Sarno A, et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab. 2013;98:372–379.
- Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr. 1987;65:823–827.
- Raymond JP, Goldstein E, Konopka P, et al. Follow-up of children born of bromocriptine-treated mothers. Horm Res. [Internet] 1985;22:239–246. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4054844
- Canales ES, Garcia IC, Ruiz JE, et al. Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil Steril. 1981;36:524–526.
- Konopka P, Raymond JP, Merceron RE, et al. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol. 1983;146:935–938.
- Lehmann WD, Musch K, Wolf AS. Influence of bromocriptine on plasma levels of prolactin and steroid hormones in the 20th week of pregnancy. J Endocrinol Investig Off J Ital Soc Endocrinol. 1979;2:251–255.
- Domingue ME, Devuyst F, Alexopoulou O, et al. Outcome of prolactinoma after pregnancy and lactation: A study on 73 patients. Clin Endocrinol (Oxf). 2014;80:642–648.
- Ono M, Miki N, Amano K, et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab. 2010;95:2672–2679.
- Lebbe M, Hubinont C, Bernard P, et al. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf). 2010;73:236–242.
- Stalldecker G, Mallea-Gil MS, Guitelman M, et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary. 2010;13:345–350.
- Faje A, Chunharojrith P, Nency J, et al. Dopamine agonists can reduce cystic prolactinomas. J Clin Endocrinol Metab. 2016;101:3709–3715.
- Jethwa PR, Patel TD, Hajart AF, et al. Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States. World Neurosurg. 2016;87:65–76.
- Zygourakis CC, Imber BS, Chen R, et al. Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J Neurol Surgery Part B Skull Base. 2017;78(2):125–131.
- Duan L, Yan H, Huang M, et al. An economic analysis of bromocriptine versus trans-sphenoidal surgery for the treatment of prolactinoma. J Craniofac Surg. [Internet] 2017;00:1–6. Available from: http://insights.ovid.com/crossref?an=00001665-900000000-96678
- Brill S. Bitter pill: how outrageous pricing and egregious profits are destroying ou health care. Time. 2013;181: 16–24. 26, 28 passim.
- Finkler SA. The distinction between cost and charges. Ann Intern Med. 1982;96:102–109.
- King JT, Justice AC, Aron DC. Management of incidental pituitary microadenomas: A cost-effectiveness analysis. J Clin Endocrinol Metab. 1997;82:3625–3632.
- King JT, Glick HA, Mason TJ, et al. Elective surgery for asymptomatic, unruptured, intracranial aneurysms: a cost-effectiveness analysis. J Neurosurg. [Internet] 1995;83:403–412. Available from: http://thejns.org/doi/10.3171/jns.1995.83.3.0403
- King JT, Sperling MR, Justice AC, et al. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. J Neurosurg. [Internet] 1997;87:20–28.
- Davis GE, Schwartz SR, Veenstra DL, et al. Cost comparison of surgery vs organ preservation for laryngeal cancer. Arch Otolaryngol Head Neck Surg. [Internet] 2005;131:21–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15655180